Bafna Pharmaceuticals (BAFNAPH) Fundamentals 2026 — P/E 50.8x, Revenue Analysis | SniperIQ
Bafna Pharmaceuticals (BAFNAPH) is a India-listed Healthcare company in Medical - Pharmaceuticals with a market capitalization of ₹564 Crore, trading at ₹238.25 on the NSE. This SniperIQ fundamentals page covers Bafna Pharmaceuticals's valuation (P/E 50.8x, P/B 5.9x), profitability (net margin 7.4%), revenue (₹151 Crore in FY2026), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Bafna Pharmaceuticals's market cap?
Bafna Pharmaceuticals (BAFNAPH) has a market capitalization of approximately ₹564 Crore, trading at ₹238.25 on the NSE. Market cap moves with the live share price.
What is Bafna Pharmaceuticals's P/E ratio?
Bafna Pharmaceuticals's trailing twelve-month P/E ratio is 50.8x, with a price-to-book (P/B) of 5.9x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Bafna Pharmaceuticals?
Bafna Pharmaceuticals runs a net profit margin of 7.4%, a gross margin of 22.7%, and an operating margin of 6.6%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Bafna Pharmaceuticals generate?
Bafna Pharmaceuticals reported revenue of ₹151 Crore for fiscal year 2026, with net income of ₹11 Crore and earnings per share (EPS) of 4.69. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Bafna Pharmaceuticals pay a dividend?
Bafna Pharmaceuticals does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Bafna Pharmaceuticals financially healthy?
Bafna Pharmaceuticals carries a debt-to-equity ratio of 0.39x and a current ratio of 1.57x, with a market beta of 0.08. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Bafna Pharmaceuticals a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Bafna Pharmaceuticals (BAFNAPH) the key facts are: market cap ₹564 Crore, P/E 50.8x, revenue ₹151 Crore, 52-week range 78.18-238.25. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Bafna Pharmaceuticals's full fundamentals live
Get Bafna Pharmaceuticals's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.